急诊PCI术后血栓前状态对术后并发症的预测

目的观察急诊经皮冠状动脉介入术后血栓前状态与术后冠脉并发症的关系。方法选择2003年至2005年期间50例因急性心肌梗死(AMI)在佛山市第二人民医院行急诊经皮冠状动脉介入术(PCI)的患者,于急诊PCI术后24h内抽取静脉血测定血栓前状态指标D-D和PAT,所有患者观察28d,根据术后有无严重冠脉并发症将患者分为两组,并发症组(A组)和非并发症组(B组),回顾性分析A、B两组的血栓前状态指标D-D和PAT,评价急诊PCI术后血栓前状态指标D-D和PAT与术后冠脉并发症的关系。结果所有50例AMI患者的血栓前状态指标D-D和PAT均较正常值升高,其中A组术后24h内D-D为(1.8±0.4)ng/L,B组D-D为(0.8±0.2)ng/L,B组明显低于A组(P<0.001);A组术后24h内PAT为(44±10)s,B组PAT为(16±5)s,B组明显低于A组(P<0.01)。结论急诊PCI术后血栓前状态指标D-D和PAT较正常值升高,D-D和PAT升高的水平是术后严重冠脉并发症的预测指标,积极降低D-D和PAT水平有可能明显降低术后严重冠脉并发症的发生率。     

大肠癌患者血浆D二聚体和纤维蛋白原浓度变化及临床意义

目的:研究大肠癌患者血浆D二聚体和纤维蛋白原浓度的变化及意义。方法:选择大肠癌患者34例及良性病患者31例,于术前采血并检测血浆D二聚体和纤维蛋白原浓度,然后进行统计分析。同时,大肠癌患者组内按照Dukes分期标准分为4组,并对组间D二聚体水平进行比较。结果:大肠癌患者的D二聚体水平显著高于对照组(P<0.05)。同样,两组之间的纤维蛋白原水平亦有显著差别,大肠癌患者组显著高于对照组(P<0.05)。在大肠癌患者的各亚组中,Dukes D期患者的D二聚体水平明显高于其他各期(P<0.05)。结论:大肠癌患者血液处于高凝状态,并且D二聚体对大肠癌的分期及预后可能有一定的指导意义。     

贝那普利对高血压病患者血浆内皮素、降钙素基因相关肽、D-二聚体水平的影响

目的：探讨贝那普利对高血压病患者血浆内皮素（ET）、降钙素基因相关肽（CGRP）、D-二聚体（D-dimer）水平的影响。方法：高血压病组（治疗组，58例）121服贝那普利[（10～20）mg／d]8周；检测治疗组治疗前、后血浆ET、CGRP、D-dimer的水平。并与对照组（38例）比较。结果：治疗前。治疗组血浆ET、D-dimer水平均较对照组明显升高（P〈0．01）；CGRP水平较对照组明显降低（P〈0.01）。治疗组口服贝那普利2周后，收缩压和舒张压明显降低（P〈0．05）；维持治疗8周，BP稳定，血浆ET、D-dimer水平则较治疗前显著降低（P〈0．01）。血浆CGRP水平较治疗前显著升高（P〈0．01）。结论：贝那普利在降低BP的同时可使高血压病患者血浆ET、D-dimer水平降低，CGRP水平升高。     

危重新生儿弥散性血管内凝血前期的监测与治疗

目的探讨监测危重新生儿血浆凝血酶原片段F1＋2、凝血酶抗凝血酶复合物（TAT）及D-二聚体等凝血及纤溶因子水平对弥散性血管内凝血前期（pre-DIC）的诊断及治疗意义。方法对NICU收治的96例危重症及36例正常新生儿检测F1＋2、TAT及D-二聚体水平，对30例诊断pre-DIC的患儿予抗凝治疗，并监测治疗后F1＋2、TAT及D-二聚体水平。结果危重症组与对照组相比，F1＋2、TAT、D-二聚体水平均增高，差异有极显著性（P均〈0．01）。TAT对pre-DIC诊断的敏感性较高，F1＋2特异性强；三者在抗凝治疗后均明显下降。F1＋2与TAT、D-二聚体三者之间均呈直线正相关，F1＋2与TAT、D-二聚体的相关系数分别为r=0．70P〈0．01；r=0.42 P〈005；TAT与D-二聚体呈正相关（r=0．35 P〈0．05）；F1＋2、TAT、D-二聚体与危重评分呈直线负相关（r=-0．68、-072、-054P均〈0.01）。结论检测TAT、F1＋2、D-二聚体水平监测危重新生儿的血液高凝状态，有助于pre—DIC的诊断，并可协助判断抗凝治疗的效果。     

缺血性脑梗死患者D-二聚体定量检测的临床研究

目的:了解缺血性脑梗死患者在不同阶段血浆D-二聚体测定的意义。方法:随机选择42例到本院神经内科就诊的缺血性脑梗死患者(年龄53~90岁,男21例,女21例),分别于急性期(<6天,n=27,年龄53~87岁)和亚急性期(6~20天,n=15,年龄51~90岁)行血浆D-二聚体测定。患者均经头颅CT证实为缺血性脑梗死。同时选择年龄相匹配的20例其他非凝血及血栓性疾病患者(年龄61~87岁)作为对照组。结果:缺血性脑梗死患者的血浆D-二聚体水平在急性期未见升高(<0.5mg/L),而在亚急性期显著升高(≥0.5mg/L,0.5~2mg/L),亚急性期与对照组(<0.5mg/L)比较差异有显著性(P<0.001),与急性期比较差异也有显著性(P<0.001)(正常值为<0.5mg/L)。结论:缺血性脑梗死患者的纤溶系统显著激活并非在急性期,而是在亚急性期。这也为急性期进行溶栓治疗提供了依据。     

The Natural Course of Serum D-Dimer,C-Reactive Protein,and Erythrocyte Sedimentation Rate Levels After Uneventful Primary Total Joint Arthroplasty

BackgroundThis study aimed to assess the baseline levels of D-dimer, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) and monitor the natural course of these serum markers after uneventful primary total joint arthroplasty.MethodsThis prospective study enrolled 81 patients undergoing primary total knee arthroplasty or total hip arthroplasty. The level of serum D-dimer, CRP, and ESR was measured preoperatively and on postoperative days 1, 3, 5, 15, and 45. Mean peak values, peak times, and distribution were compared between D-Dimer, CRP, and ESR.ResultsThe mean preoperative serum D-dimer, CRP, and ESR level was 412 ± 260 (range 200-980) ng/mL, 2.93 ± 2.1 (range 1-18) mg/L, and 22.88 ± 17.5 (range 3-102) mm/h, respectively. The highest mean peak for D-dimer, CRP, and ESR was at postoperative day 1, 3, and 5, respectively.ConclusionD-dimer levels reached peak levels on postoperative day 1 and then declined rapidly to a plateau level by postoperative day 3. A second, albeit small, peak in the level of D-dimer occurred on postoperative day 15. The level of CRP and ESR remained elevated for much longer with CRP returning to baseline on postoperative day 45 and the level of ESR had not returned back to normal on postoperative day 45.     

糖尿病肾病患者D-二聚体、纤维蛋白原、胱抑素C检测价值分析

目的分析糖尿病肾病患者D-二聚体、纤维蛋白原、胱抑素C检测价值分析。方法选择2019年7月—2020年7月该院收治糖尿病肾病患者50例作为研究组,选择同期接受健康体检者50名为对照组,两组均检测D-二聚体、纤维蛋白原、胱抑素C指标,对两组检测价值进行比较。结果研究组D-二聚体、纤维蛋白原、胱抑素C、肌酐、HbA1c指标分别为(2.31±1.02)μg/mL、(4.58±1.07)g/L、(3.77±1.14)mg/L、(383.09±133.55)mmol/L、(7.48±1.56)%,各指标均比对照组高,差异有统计学意义(t=8.061、10.608、20.048、16.643、15.989,P<0.05);对比两组甘油三酯指标,差异无统计学意义(t=1.352,P>0.05);将糖化血红蛋白指标7%作为临界点,对比Cys-C指标(3.47±1.76)mg/L,糖化血红蛋白指标<7%患者的Cys-C水平比糖化血红蛋白指标≥7%患者低,比较差异有统计学意义(t=2.259,P<0.05)。结论纤维蛋白原、胱抑素C、D-二聚体可作为糖尿病肾病患者发生及发展的重要参考指标,对于监测该疾病的发生和发展存在一定意义。     

Cerebral venous thrombosis in COVID-19-associated coagulopathy: A case report

COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first reported in Wuhan, China in December 2019, and is ongoing pandemic. While a majority of patients with SARS-CoV-2 infection shows asymptomatic or mild disease, hospitalized patients can develop critical condition, such as pneumonia, sepsis, and respiratory failure. Some cases deteriorate into sever systemic disease and multiorgan failure. Many patients of severe COVID-19 show hypercoagulable state and complicate with venous thromboembolism and atrial thrombosis. We herein reported a case of COVID-19 who developed cerebral venous thrombosis (CVT) co-incidence with pulmonary thromboembolism (PTE). A 56-year-old Japanese man was presented with fever and malaise and diagnosed with COVID-19. He was treated with ciclesonide and azithromycin, but his respiratory condition deteriorated. Thus, systemic corticosteroids and favipiravir were initiated and these treatments resulted in afebrile state, improving malaise and respiratory failure. However, he suddenly developed severe headache and vomiting with increased concentration of D-dimer. Brain CT and MRI showed typical images of CVT in the left transvers sinus and CT pulmonary angiography showed PE. Administration of unfractionated heparin followed by edoxaban treatment reduced the levels of D-dimer and improved his clinical presentation and thrombosis. Monitoring coagulopathy is important in COVID-19 patients and in case of venous thromboembolism, including cerebral venous system, appropriate anticoagulant therapy should be initiated.     

Relation of D-dimer levels of COVID-19 patients with diabetes mellitus

Background and aimsDiabetes is a frequent comorbidity in patients with Severe COVID-19 infection associated with a worse prognosis. Hypercoagulability with elevation in D-dimer levels has been demonstrated in patients with COVID-19. This study aims to study D-dimer levels in people with diabetes compared to those without diabetes among patients with COVID-19 infection.MethodsIn this observational study 98 moderate and severely ill patients with COVID-19 infection were included at a dedicated COVID hospital. The study group was divided into patients with diabetes and without diabetes. Peak D-dimer was measured in both the groups and compared using appropriate statistical tests.ResultsIn our study peak D-dimer levels were 1509 ± 2420 ng/mL (Mean ± SD) in people with diabetes and 515 ± 624 ng/mL (Mean ± SD) in patients without diabetes. Patients with diabetes had higher D-dimer levels which were statistically significant.ConclusionsThis study shows COVID-19 patients with diabetes had significantly higher D-dimer levels. Therefore, it is possible that COVID-19 infection with diabetes is more likely to cause hypercoagulable state with a worse prognosis. However clinical implications of these findings will need to be seen in further studies.